Jason Zemansky
BofA Securities, Research Division

[Audio Gap] care conference in very toasty Las Vegas. I'm very pleased to be up here this morning with Todd Harris, Chief Executive Officer of Tyra Biosciences. Todd is going to run us through a few slides, and then we'll open up to Q&A. So Todd?

Todd Harris
Co-Founder, CEO, President & Director

Thanks, Jason. It's great to be here. Thanks for having us. So I will be making some forward-looking statements today. Excited to highlight just upfront here what we talk about -- when we talk about Tyra and our dabo 3x3 strategy. It's a very exciting year for us. It's a very exciting few years coming up for us. We have 3 potential blockbuster indications. Going into late-stage development with our lead drug, dabogratinib, a drug that has been validated in a Phase I study in a late-line metastatic as being a highly selective, very well-tolerated FGFR3 selective inhibitor. It's touched over 100 patients today.

And in the 3 indications that we're talking about, these are validated indications where FGFR3 inhibition has already demonstrated very meaningful outcomes, but where the current drugs by inhibiting other isoforms have run into significant toxicity challenges. It's where dabogratinib can truly stand apart. And to just highlight these indications, and they're quite compelling.

In urothelial carcinoma, there's about 80,000 new patients a year. There's 700,000 patients worldwide with bladder cancer. FGFR3 mutations, and they're very specific ones, drive nearly half of these. But in the intermediate risk setting, low grade and in the low-grade upper tract setting, 75%, 70%, 80%, 85% rates of FGFR3 positivity. So this is where the